Valuation Today: InflaRx N.V. (NASDAQ: IFRX)

InflaRx N.V. is part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Niels Riedemann. InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.

Previous Intraday Performance:

The IFRX shares had a previous change of -5.60% which opened at 43.00 and closed at 40.60. It moved to an intraday high of 43.00 and a low of 39.93.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, IFRX shares returned -12.05% and in the past 30 trading days it returned 20.83%. Over three months, it changed 45.83%. In one year it has changed 30.30% and within that year its 52-week high was 51.33 and its 52-week low was 20.31. IFRX stock is 99.90% above its 52 Week Low.

Our calculations result in a 200 day moving average of 33.37 and a 50 day moving average of 37.51. Right now, IFRX stock is trading 21.67% above its 200 day moving average.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa


The company has a market cap of $1.1b with 25.9m shares outstanding and a float of 25.9m shares. Trading volume was 307,071 shares and has experienced an average volume of 176,324 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for InflaRx N.V. was -3.12 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.44.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.31
06-30-2018:  -0.12
03-31-2018:  -0.49

The next earnings report will be: 04-04-2019

EPS growth is an important number as it indicates the future prospects of InflaRx N.V..

Indicators Also to Watch:

Based on the latest filings, there is 56.10% of institutional ownership.

I calculated the beta to be -0.82

SeekingAlpha:  Are There Some New Dents In Main Street Capital’s Armor? (Investment Ratings Analysis)

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -51.21%, return on assets is -33.08% and price-to-book is 6.23.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Tags: , , ,

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *